Cinqair (reslizumab) does not treat all types of asthma. It has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance therapy to treat patients with severe asthma, aged 18 years and older, who have an eosinophilic phenotype.
Cinqair is not used to treat other types of asthma, other eosinophilic conditions, or used as a rescue medication for asthma attacks.